Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use

Details for Australian Patent Application No. 2011237936 (hide)

Owner F. Hoffmann-La Roche AG

Inventors Wang, Xiaojing

Agent Griffith Hack

Pub. Number AU-A-2011237936

PCT Pub. Number WO2011/124580

Priority 61/321,588 07.04.10 US

Filing date 6 April 2011

Wipo publication date 13 October 2011

International Classifications

C07D 401/12 Heterocyclic compounds containing two or more hetero rings

A61K 31/4155 - not condensed and containing further heterocyclic rings

A61P 35/00 Antineoplastic agents

C07D 401/14 Heterocyclic compounds containing two or more hetero rings

C07D 403/12 Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

C07D 403/14 Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

C07D 417/12 Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

C07D 417/14 Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

Event Publications

11 October 2012 PCT application entered the National Phase

  PCT publication WO2011/124580 Priority application(s): WO2011/124580

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2011237946-Aluminium die casting alloy

2011237922-Antibody recognizing human Leukemia Inhibitory Factor (LIF) and use of antiLIF antibodies in the treatment of diseases associated with unwanted cell proliferation